Your browser is no longer supported. Please, upgrade your browser.
Settings
RNA [NASD]
Avidity Biosciences, Inc.
Index- P/E- EPS (ttm)-1.66 Insider Own10.97% Shs Outstand37.52M Perf Week-12.19%
Market Cap755.21M Forward P/E- EPS next Y-3.60 Insider Trans-1.42% Shs Float33.49M Perf Month-21.85%
Income-62.10M PEG- EPS next Q-0.71 Inst Own91.80% Short Float18.10% Perf Quarter-17.62%
Sales8.10M P/S93.24 EPS this Y-265.90% Inst Trans0.40% Short Ratio28.04 Perf Half Y-15.60%
Book/sh7.63 P/B2.53 EPS next Y-18.00% ROA-18.40% Target Price- Perf Year-31.06%
Cash/sh7.87 P/C2.45 EPS next 5Y- ROE-20.00% 52W Range18.85 - 37.46 Perf YTD-24.33%
Dividend- P/FCF- EPS past 5Y- ROI-14.50% 52W High-48.45% Beta-
Dividend %- Quick Ratio17.80 Sales past 5Y- Gross Margin- 52W Low2.44% ATR1.81
Employees71 Current Ratio17.80 Sales Q/Q92.90% Oper. Margin- RSI (14)36.28 Volatility8.02% 8.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-361.60% Profit Margin- Rel Volume0.63 Prev Close20.08
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume216.21K Price19.31
Recom1.80 SMA20-15.17% SMA50-18.66% SMA200-23.52% Volume136,230 Change-3.83%
Jun-17-21Initiated Needham Buy $50
Apr-26-21Resumed Credit Suisse Outperform $37
Jul-07-20Initiated Wells Fargo Overweight $60
Jul-07-20Initiated Wells Fargo Overweight
Jul-07-20Initiated SVB Leerink Outperform
Jul-07-20Initiated Credit Suisse Outperform $34
Jul-07-20Initiated Credit Suisse Outperform
Jul-07-20Initiated Cowen Outperform
Jun-17-21 10:43AM  
May-19-21 09:00AM  
May-12-21 04:05PM  
May-11-21 09:39AM  
May-03-21 08:54AM  
Apr-16-21 09:00AM  
Mar-25-21 04:05PM  
Mar-15-21 04:05PM  
07:40AM  
Feb-17-21 04:05PM  
Jan-21-21 08:30AM  
Jan-11-21 08:30AM  
Jan-08-21 08:30AM  
Dec-22-20 04:05PM  
Dec-21-20 04:05PM  
Dec-19-20 01:06PM  
Nov-10-20 04:05PM  
Nov-05-20 04:05PM  
Sep-14-20 04:05PM  
03:58PM  
Sep-08-20 08:00AM  
Sep-03-20 04:05PM  
Aug-10-20 04:05PM  
Jul-27-20 08:00AM  
Jul-23-20 08:14PM  
Jun-26-20 10:12PM  
Jun-19-20 01:24PM  
Jun-16-20 04:01PM  
Jun-12-20 11:56AM  
06:33AM  
Jun-11-20 08:54PM  
02:42PM  
06:28AM  
Jun-10-20 07:24AM  
Jun-08-20 06:55AM  
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEVIN ARTHUR AChief Scientific OfficerJun 25Option Exercise1.1320,10022,73521,430Jun 28 07:21 PM
LEVIN ARTHUR AChief Scientific OfficerJun 25Sale28.1220,100565,2991,330Jun 28 07:21 PM
LEVIN ARTHUR AChief Scientific OfficerJun 24Option Exercise1.241001241,430Jun 28 07:21 PM
LEVIN ARTHUR AChief Scientific OfficerJun 24Sale27.751002,7761,330Jun 28 07:21 PM
LEVIN ARTHUR AChief Scientific OfficerJun 17Option Exercise1.242002481,530Jun 22 08:24 PM
LEVIN ARTHUR AChief Scientific OfficerJun 17Sale27.752005,5501,330Jun 22 08:24 PM
LEVIN ARTHUR AChief Scientific OfficerJun 15Sale26.0223,019599,0670Jun 16 08:21 PM
LEVIN ARTHUR AChief Scientific OfficerJun 14Sale25.9214,003362,92123,019Jun 16 08:21 PM
LEVIN ARTHUR AChief Scientific OfficerMar 16Option Exercise0.944,6004,3024,600Mar 18 09:39 PM
LEVIN ARTHUR AChief Scientific OfficerMar 16Sale27.874,600128,1810Mar 18 09:39 PM